
SMITH & NEPHEW PLC -SPON ADR
SNNNYSETrading Snapshot
- Day Range
- $29.47 β $30.39
- 52-Week Range
- $28.56 β $38.79
- Volume
- $2.35B
- Avg Volume
- $2.53B
- Shares Outstanding
- 419.9M
- Next Earnings
- Oct 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $6.16B
- Last Q Revenue
- $3.10B
- P/E Ratio
- 19.4
- P/S Ratio
- 1.9x
- EPS (TTM)
- $1.51
- Dividend Yield
- 2.66%
Why Investors Own SNN
- βHigh-growth profile β revenue up +13.3% YoY with expanding US Equity exposure.
- βHealthy economics β 72% gross margin and 16% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SMITH & NEPHEW PLC -SPON ADR
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates

Smith & Nephew plc (SNN) Q2 2026 Earnings Call Transcript
Smith & Nephew plc (SNN) Q2 2026 Earnings Call August 4, 2026 6:30 AM EDTCompany ParticipantsDeepak Nath - CEO & DirectorJohn Rogers - CFO &...

Smith & Nephew plc 2026 Q2 - Results - Earnings Call Presentation
2026-08-04. The following slide deck was published by Smith & Nephew plc in conjunction with their 2026 Q2 earnings call.

Powell Industries Posts Downbeat Q3 Results, Joins Clearpoint Neuro, Ichor Holdings And Other Big Stocks Moving Lower In Tuesdayβs Pre-Market Session
U.S. stock futures rise on Tuesday, but Powell Industries Inc shares fall 13.4% after reporting lower-than-expected earnings and sales.
CORRECTION: Smith & Nephew Lowers FY2026 Sales Guidance from $6.534B to $6.411B vs $6.565B Est
Smith & Nephew (NYSE:SNN) lowers FY2026 sales outlook from $6.534 billion to $6.411 billion vs $6.565 billion estimate.
Smith+Nephew's ESSA Spatial Surgery System Receives FDA's De Novo Classification
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been granted De Novo classification by the U.S. Food & Drug Administration (FDA) for its TESSA Spatial Surgery System.